Related Experiment Video

Updated: Jun 20, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta

Matthew R Farren1, Louise M Carlson, Kelvin P Lee

  • 1Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

Immunologic Research
|September 17, 2009
PubMed

Insights

Tumors suppress the immune system by hindering dendritic cell differentiation via Stat3 activation. This leads to decreased dendritic cells and increased immunosuppressive cells, potentially impacting cancer immunotherapy success.

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Signaling

Background:

  • Tumor-induced immune suppression involves dysregulated dendritic cell differentiation.
  • This leads to fewer dendritic cells and more immunosuppressive myeloid-derived suppressor cells, hindering anti-cancer immunotherapy.
  • Tumor-mediated myeloid dysregulation is Stat3-dependent, but the precise molecular mechanism is unclear.

Purpose of the Study:

  • To elucidate the molecular mechanism of Stat3 signaling in tumor-mediated myeloid dysregulation.
  • To investigate the role of Protein Kinase C betaII (PKC betaII) in dendritic cell differentiation and its regulation by tumor-associated Stat3 signaling.

Main Methods:

  • Analyzing Stat3 activation and PKC betaII expression in dendritic cell progenitor cells from tumor-bearing models.
  • Utilizing a constitutive active Stat3 mutant to mimic tumor-induced signaling effects.
  • Assessing the impact of Stat3 activation on dendritic cell differentiation pathways.

Main Results:

  • Tumors induce Stat3 activation in dendritic cell progenitor cells.
  • Tumors also cause a downregulation of PKC betaII in these cells.
  • Expression of a constitutively active Stat3 mutant replicated the observed downregulation of PKC betaII.

Conclusions:

  • Tumor-mediated immune suppression involves Stat3-induced downregulation of PKC betaII in dendritic cell progenitors.
  • This molecular mechanism links Stat3 signaling to impaired dendritic cell differentiation.
  • Targeting this pathway may offer a strategy to overcome immune suppression and improve anti-cancer immunotherapy.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...